Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ILLUMINATE-SA
- Sponsors Novartis Pharmaceuticals
- 24 Jan 2025 New trial record